Cue Biopharma Appoints James Ahlers as CFO

What Happened
Cue Biopharma, Inc. announced that its Board appointed James Ahlers as Chief Financial Officer, effective July 30, 2026. Mr. Ahlers will serve as the company’s principal financial officer. He entered into an executive employment agreement dated July 28, 2026, which sets his pay, bonus opportunity and other compensation terms. The filing describes his extensive finance and life‑sciences experience, including prior CFO roles and advisory work related to public and private financings, SEC reporting and IPO readiness.

Key Details

• Effective date: July 30, 2026; employment agreement dated July 28, 2026.
• Base salary: $450,000 per year.
• Annual incentive: discretionary bonus with a target of up to 45% of base salary.
• Inducement equity grants (under the 2026 Inducement Stock Incentive Plan): a nonstatutory stock option and restricted stock units (RSUs). The grant terms specify an option exercise price of $30.40 (closing Nasdaq price on the effective date) and RSUs for 25,500 shares. (The filing lists the option share number as “51,00,” which appears to be a typographical error and is reported here as 51,000 shares.) Grants vest in equal quarterly installments over four years, subject to continued service.
• Severance for qualifying termination (termination by company other than for Cause or by executive for Good Reason): lump‑sum equal to nine months’ base salary plus the prorated target bonus for the year; COBRA premiums paid for up to nine months (subject to earlier events); other applicable benefits.
• Change‑in‑control protection: if a qualifying termination occurs within the 90 days before or 24 months after a change in control, time‑vested awards accelerate in full and service conditions on performance awards are treated as satisfied (performance measured at greater of target or actual), with extended post‑termination exercise periods.
• Mr. Ahlers signed the company’s standard indemnification agreement. The filing reports no related‑party transactions or family relationships requiring disclosure.

Why It Matters
A new CFO with broad life‑science finance experience can affect how the company manages public reporting, compliance and fundraising. The compensation package combines cash pay, a sizable bonus target and equity incentives to align the CFO’s interests with shareholder value and retention over four years. The change‑in‑control and severance protections are notable items for governance and potential transaction scenarios. Investors should note the equity grant terms (exercise price equals recent market price) and the potential dilution from grants, and watch for future filings (Form 10‑Q exhibits) that will include the full employment agreement text.